Hormone Therapy Risks: Put the Headlines in Numbers

Someone tells you hormone therapy should never be used. Someone else tells you it is safer than water and every concern was invented by a newspaper in 2002. Both have managed to make a medical decision sound like a team sport. You want the actual numbers, what they measured, and whether those numbers apply to you.

The plain version: systemic hormone therapy is the most effective treatment for hot flashes and night sweats, and its risks are real but not identical for everyone. Age, time since menopause, medical history, whether you have a uterus, the treatment used and how long it is used all matter. The original Women’s Health Initiative results belong in the conversation with their absolute numbers and their study population attached. People who cannot or do not want to use systemic hormones have evidence-based alternatives.

What’s going on

Systemic hormone therapy supplies estrogen to the body through a route such as a pill, patch or gel. It can reduce hot flashes and night sweats and help prevent bone loss while it is taken [1] [2]. If you have a uterus, estrogen without adequate progestogen can cause the uterine lining to thicken and increase endometrial-cancer risk. That is why a clinician ordinarily includes a progestogen. After hysterectomy, estrogen alone may be used. These are different regimens with different evidence; lumping them together under “HRT” obscures a key part of the decision [2].

Low-dose vaginal estrogen is another category. It acts mainly where it is placed and is used for vaginal and urinary symptoms, not for hot flashes. It should have its own discussion rather than inheriting every risk headline about systemic therapy. If you have a personal history of hormone-sensitive cancer, involve the appropriate clinicians in even that local decision [1].

The timing question matters too. The Menopause Society’s 2022 statement says the benefit-risk ratio for treatment of bothersome symptoms is generally favorable for women younger than 60 or within 10 years of menopause onset when they have no contraindication. Starting after 60 or more than 10 years after menopause usually brings a less favorable balance because risks such as coronary disease, stroke, venous thromboembolism and dementia rise with age and timing [1]. This is guidance for a discussion, not a guarantee of safety for every 59-year-old or a ban on every 61-year-old.

What the original WHI numbers say

In the 2002 Women’s Health Initiative trial of a specific oral estrogen-plus-progestin regimen, the absolute excess per 10,000 person-years was 7 additional coronary heart-disease events, 8 strokes, 8 pulmonary emboli and 8 invasive breast cancers. The same report found 6 fewer colorectal cancers and 5 fewer hip fractures per 10,000 person-years [4]. “Person-years” means the number of people multiplied by their years of observation. It is not the number of people who will have an event over an entire lifetime.

Those figures are far more useful than saying breast-cancer risk rose by a percentage with no starting rate. They are also not a personal calculator. The trial included postmenopausal women across a broad age range, many older than someone considering therapy soon after the final period. It studied one oral formulation, not every current regimen. Randomization makes its comparison powerful for that formulation and population; it does not make every modern treatment equivalent.

The estrogen-alone WHI trial enrolled people who had had a hysterectomy. It did not show the same breast-cancer pattern as the combined trial; it did show 12 additional strokes per 10,000 person-years and 6 fewer hip fractures for outcomes significantly affected in that trial [5]. Do not average the two trials together to produce one reassuring or frightening number. Whether the uterus is present changes the treatment and the evidence.

Risk also depends on the outcome you are discussing. Breast cancer, clotting, stroke, fractures and symptom relief do not move in lockstep. A person’s history of a prior clot can matter more to the decision than a small average change in a different outcome. Ask the clinician which risks are most relevant to your history and which numbers they are using.

The WHI report is also a lesson in denominators. Eight additional invasive breast cancers per 10,000 person-years is about eight additional cases among 10,000 people followed for one year, on average in that trial. It does not mean one in eight people developed cancer, and it does not mean the same extra eight people are counted every year indefinitely. Risk can change with duration of treatment and baseline health. If a handout gives you only a relative percentage, ask for the starting number and the time period. Without those, the percentage can sound much larger or smaller than the decision really is [4].

What helps, and how well

For disruptive hot flashes and night sweats, systemic hormone therapy has the strongest evidence and remains a reasonable option for many eligible people [1]. A clinician should review medical history, medications, bleeding pattern, whether you have a uterus, and the goals of treatment before discussing route and regimen. Systemic therapy is generally not recommended for someone with certain hormone-sensitive cancers, a history of stroke, heart attack, blood clots or serious liver disease [2]. A family history is a different question from a personal history and deserves a more precise discussion than a blanket yes or no.

If you cannot or choose not to use systemic hormone therapy, nonhormonal prescription treatments, menopause-focused CBT and clinical hypnosis have evidence for vasomotor symptoms [6]. These are substantive choices, not consolation prizes. If vaginal dryness or pain is the main problem, local treatments may be more relevant than systemic therapy. If mood or insomnia is the main problem, that may call for its own assessment and treatment rather than assuming a hot-flash prescription will solve everything.

No route or regimen should be sold as risk-free. A patch may have a different clotting profile from an oral formulation, but the quality of evidence varies by outcome, and one advantage does not erase other considerations. NICE advises discussing benefits and risks by treatment type and using shared decision-making [3]. Ask for the comparison the clinician is actually making: this treatment versus no treatment, versus a nonhormonal medicine, or versus another hormone route.

How strong is the evidence? The WHI trials are randomized and large, so their measured outcomes deserve serious attention. Their absolute event numbers apply most directly to the regimens and populations they studied. Current guidelines combine those trials with later evidence and clinical judgment about timing, formulation and individual risk. Claims that all hormone therapy is either harmless or unacceptable outrun the evidence in opposite directions.

Questions the headline could not answer

First, what symptom are you treating? Someone who has a few tolerable flashes has a different benefit to weigh from someone who cannot sleep through the night. If the main issue is vaginal dryness, local therapy may address it without systemic treatment. The same risk is weighed differently when the expected benefit changes.

Second, what is your baseline risk? Prior blood clots, cardiovascular disease, breast cancer, unexplained vaginal bleeding and liver disease change the discussion. Family history and personal history should be distinguished, and the specifics matter. Your clinician may need to investigate bleeding before starting therapy. This is why a risk number from a trial cannot be pasted onto a stranger in a waiting room.

Third, how will the plan be reviewed? Symptoms change, priorities change and new health conditions appear. The 2022 Menopause Society statement calls for periodic reevaluation of benefit and risk [1]. Ask when you will check whether treatment is meeting its goal and what new symptom should trigger a call sooner. There is no need to decide the next decade in one appointment.

Finally, ask about the alternative you would choose if the first option did not fit. A clinician who explains only one path has left you with an incomplete map. A person can make a thoughtful choice to use systemic hormones, a thoughtful choice to use a nonhormonal approach, or a thoughtful choice to defer treatment. The good decision is the one made with the relevant evidence and your own priorities visible.

If you have been told that a “bioidentical” custom blend is categorically safer, ask which regulated product and which outcome the claim refers to. A familiar-sounding chemical name is not a clinical trial. The decision should be built around a defined formulation with known ingredients and a monitored plan, not a promise that the word natural removes uncertainty. The same standard applies to alarming claims in the opposite direction: name the formulation, outcome, comparison and absolute risk before treating the headline as your forecast.

Take this to your appointment

• “Which symptom are we trying to improve, and how much improvement should I expect?”
• “Do my age, time since menopause and medical history make systemic hormone therapy a reasonable option?”
• “I have [or have not had] a hysterectomy. How does that change the regimen and the evidence?”
• “Can you give me absolute risk numbers for the outcome most relevant to me, and explain which study they come from?”
• “If systemic hormones are unsuitable or not my preference, which evidence-based alternatives fit?”
• “When will we review benefits, side effects and whether to continue?”

See a clinician promptly if… you have any bleeding after 12 months without a period, very heavy or prolonged bleeding, new chest pain, a painful swollen leg or sudden shortness of breath, or low mood that won’t lift. If you are thinking about harming yourself, call or text 988 in the US, or call 911 in an emergency. This article is general education, not medical advice.

For the other side of the decision, read nonhormonal hot-flash treatments and the menopause appointment checklist.